Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.

Sun HC, Zhu XD, Shen F, Song TQ, Bai XL, Zeng YY, Chen MS, Huang ZY, Cai JQ, Gao J, Kuang M, Li DY, Xing BC, Li XC, Wen TF, Peng T, Wang YD, Liu LX, Huang C, Shi YH, Huang XW, Wang K, Gao Q, Zhou J, Fan J

Open source

DOI: 10.1016/s0140-6736(26)01252-3
Published: 2026 Aug 22
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-01252-3,
  title = {Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.},
  author = {Sun HC and Zhu XD and Shen F and Song TQ and Bai XL and Zeng YY and Chen MS and Huang ZY and Cai JQ and Gao J and Kuang M and Li DY and Xing BC and Li XC and Wen TF and Peng T and Wang YD and Liu LX and Huang C and Shi YH and Huang XW and Wang K and Gao Q and Zhou J and Fan J},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)01252-3},
  url = {https://doi.org/10.1016/s0140-6736(26)01252-3}
}

RIS

TY  - JOUR
TI  - Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.
AU  - Sun HC
AU  - Zhu XD
AU  - Shen F
AU  - Song TQ
AU  - Bai XL
AU  - Zeng YY
AU  - Chen MS
AU  - Huang ZY
AU  - Cai JQ
AU  - Gao J
AU  - Kuang M
AU  - Li DY
AU  - Xing BC
AU  - Li XC
AU  - Wen TF
AU  - Peng T
AU  - Wang YD
AU  - Liu LX
AU  - Huang C
AU  - Shi YH
AU  - Huang XW
AU  - Wang K
AU  - Gao Q
AU  - Zhou J
AU  - Fan J
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)01252-3
UR  - https://doi.org/10.1016/s0140-6736(26)01252-3
ER  -

APA

HC, S., XD, Z., F, S., TQ, S., XL, B., YY, Z., MS, C., ZY, H., JQ, C., J, G., M, K., DY, L., BC, X., XC, L., TF, W., T, P., YD, W., LX, L., C, H., YH, S., XW, H., K, W., Q, G., J, Z., & J, F. (2026). Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)01252-3

Source records

pubmed · retrieved 2026-09-25T18:53:08.621Z